141 – 150 of 247
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales
(
- Contribution to journal › Letter
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Matrix Glycoproteins and Proteoglycans in Cartilage
(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
CNI-1493, an inhibitor of proinflammatory cytokines, retards cartilage destruction in rats with collagen induced arthritis
(
- Contribution to journal › Article
-
Mark
Response criteria for rheumatoid arthritis in clinical practice - how useful are they?
(
- Contribution to journal › Article
-
Mark
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
(
- Contribution to journal › Article
- 2004
-
Mark
Hormone replacement therapy, calcium and vitamin D-3 versus calcium and vitamin D-3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456]
(
- Contribution to journal › Article
-
Mark
Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al
(
- Contribution to journal › Letter
-
Mark
Fibronectin fragments cause release and degradation of collagen-binding molecules from equine explant cultures.
(
- Contribution to journal › Article